Clinical trials: Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome-IBS
Evaluate the Safety of Linaclotide in IBS-C Patients in China
This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for…
- Trial name
- Liberty (NCT04462900)
- Where
- 29 sites in China
- Volunteers
- 3,028 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
IBS, Constipation Predominant
The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation
The study will aim to evaluate the effectiveness of the use of a food supplement, based on a green tea extract (Camellia sinensis (L.) Kuntze - folium) and a pool of probiotics (L. plantarum, L. rhamnosus and B. animalis subsp.
- Trial name
- NCT07094035
- Testing
- food supplement based on a mixture of green tea extract and a pool of probiotics.
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Adamas Biotech S.r.l.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation
- Trial name
- NCT02493036
- Testing
- SYN-010
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation, Functional Constipation
IBS-C Questionnaire Study
The study is a multi-centre, observational study which enrolls 150 IBS-C patients and 150 non-IBS-C patients in China.
- Trial name
- NCT04968652
- Where
- 10 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity
- Trial name
- NCT04662502
- Testing
- Bifidobacterium longum 35624
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Biocodex
Diarrhea
Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.
This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea.
- Trial name
- NCT05816681
- Testing
- DWJ1230, DWB2001
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
- Trial name
- IRIS (NCT00761007)
- Testing
- Ibodutant
- Where
- 6 sites in Denmark, Germany and 4 more
- Volunteers
- 554 people
- Sponsor
- Menarini Group
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will evaluate the effects of ORP-101 versus placebo on stool consistency and abdominal pain in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D).
- Trial name
- NCT04129619
- Testing
- ORP-101
- Where
- 74 sites in United States
- Volunteers
- 321 people
- Sponsor
- OrphoMed, Inc.
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
IBS - Irritable Bowel Syndrome
Effect of Postbiotic Product on Colonic Barriers in IBS
Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS).
- Trial name
- NCT05475314
- Testing
- ReFerm(R)
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Nordisk Rebalance A/S